Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Convertible Debt (2020 - 2025)

Historic Convertible Debt for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q2 2025 value amounting to $93.5 million.

  • Apellis Pharmaceuticals' Convertible Debt rose 33.7% to $93.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $93.5 million, marking a year-over-year increase of 33.7%. This contributed to the annual value of $93.3 million for FY2024, which is 33.11% up from last year.
  • Apellis Pharmaceuticals' Convertible Debt amounted to $93.5 million in Q2 2025, which was up 33.7% from $93.4 million recorded in Q1 2025.
  • Apellis Pharmaceuticals' 5-year Convertible Debt high stood at $386.5 million for Q2 2021, and its period low was $92.7 million during Q3 2022.
  • Its 5-year average for Convertible Debt is $147.0 million, with a median of $93.3 million in 2024.
  • Its Convertible Debt has fluctuated over the past 5 years, first soared by 16712.05% in 2021, then crashed by 5112.97% in 2022.
  • Apellis Pharmaceuticals' Convertible Debt (Quarter) stood at $189.0 million in 2021, then crashed by 50.94% to $92.7 million in 2022, then increased by 0.32% to $93.0 million in 2023, then increased by 0.33% to $93.3 million in 2024, then grew by 0.17% to $93.5 million in 2025.
  • Its last three reported values are $93.5 million in Q2 2025, $93.4 million for Q1 2025, and $93.3 million during Q4 2024.